The First Affiliated Hospital of Xiamen University
xmfh.com.cnLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
111
Active
65
Phase 3
3
Total enrollment
24,577
Pipeline matrix
Showing 40 of 59 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| semaglutide combined with metformin | — | — | — | — | — | 1 | |
| Liraglutide | — | — | — | — | — | 1 | |
| insulin glargine | — | — | — | — | — | 1 | |
| Apatinib Mesylate | — | — | — | — | 3 | ||
| Mycophenolate Mofetil, Oral, 250 Mg | — | — | — | — | — | 1 | |
| methimazole, oral, 10mg | — | — | — | — | — | 1 | |
| Fluzoparib | — | — | — | — | — | 1 | |
| Adebrelimab | — | — | — | — | — | 2 | |
| Intravenous the dose of esketamine ED95 | — | — | — | — | — | 2 | |
| Tislelizumab | — | — | — | — | — | 2 | |
| Apatinib | — | — | — | — | — | 2 | |
| Intravenous esketamine using Dixon's up-and-down sequential method | — | — | — | — | — | 1 | |
| Intravenous fentanyl 1 μg∙kg-1 | — | — | — | — | — | 1 | |
| CAR-T treatment | — | — | — | — | — | 1 | |
| Large fraction radiotherapy in combined with GM-CSF, Lenalidomide, and Glofitamab | — | — | — | — | — | 1 | |
| Rezvilutamide | — | — | — | — | — | 1 | |
| Goserelin Microspheres for | — | — | — | — | — | 1 | |
| Docetaxel | — | — | — | — | — | 1 | |
| Pamiparib | — | — | — | — | — | 1 | |
| Cisplatin | — | — | — | — | — | 1 | |
| Adebrelimab+Albumin paclitaxel +Cisplatin | — | — | — | — | — | 1 | |
| Paclitaxel for | — | — | — | — | — | 1 | |
| Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimen | — | — | — | — | — | 1 | |
| Chidamide combined with Linperlisib | — | — | — | — | — | 1 | |
| Trilaciclib and Sacituzumab Tirumotecan | — | — | — | — | — | 1 | |
| Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections | — | — | — | — | — | 1 | |
| Recombinant Human Interleukin-2 Injections | — | — | — | — | — | 1 | |
| Chidamide combined with Duvillisib | — | — | — | — | — | 1 | |
| Tofacitinib | — | — | — | — | — | 1 | |
| Trilaciclib combined with Docetaxel | — | — | — | — | — | 1 | |
| veneclax, chidaniline combined with azacitidine | — | — | — | — | — | 1 | |
| Iparomlimab/Tuvorlimab(QL-1706) and modified TPF regimen | — | — | — | — | — | 1 | |
| albumin-bound paclitaxel | — | — | — | — | — | 1 | |
| Nedaplatin | — | — | — | — | — | 1 | |
| Two-cycle induction chemotherapy + immunotherapy | — | — | — | — | — | 1 | |
| Three-cycle induction chemotherapy + immunotherapy | — | — | — | — | — | 1 | |
| IMRT combined with lobaplatin-based concurrent chemotherapy | — | — | — | — | — | 1 | |
| venetoclax combining chidamide and azacitidine | — | — | — | — | — | 1 | |
| Pyrotinib Maleate Tablets + Dalpiciclib Isethionate Tablets + Standard Endocrine | — | — | — | — | — | 1 | |
| TACE with adebrelimab and bevacizumab | — | — | — | — | — | 1 |
19 more active programs hidden
Next readouts
- 2025-01-15
- 2025-10-08
- 2025-12-01
- 2025-12-20
- 2025-12-30
- 2025-12-31
- 2025-12-31
- 2025-12-31
- 2026-01-31
- 2026-03-01
Top conditions
- PET/CT8
- Positron-Emission Tomography6
- Tumor4
- Follicular Lymphoma4
- Acute Myeloid Leukemia3
- Tumor, Solid3
- Solid Tumor3
- Ovarian Cancer3
Frequently asked questions about The First Affiliated Hospital of Xiamen University
- How many clinical trials does The First Affiliated Hospital of Xiamen University have on ClinicalTrials.gov?
- The First Affiliated Hospital of Xiamen University is listed as the lead sponsor on 111 clinical trials in ClinicalTrials.gov, 65 of which are currently active (recruiting, enrolling, or ongoing).
- How many of The First Affiliated Hospital of Xiamen University's trials are in Phase 3?
- 3 of The First Affiliated Hospital of Xiamen University's trials are in Phase 3, spread across 59 active drug programs.
- What therapeutic areas does The First Affiliated Hospital of Xiamen University focus on?
- The First Affiliated Hospital of Xiamen University's most-studied conditions on ClinicalTrials.gov are PET/CT, Positron-Emission Tomography, Tumor, Follicular Lymphoma, Acute Myeloid Leukemia.
- When are The First Affiliated Hospital of Xiamen University's next clinical trial readouts?
- The First Affiliated Hospital of Xiamen University has 10 upcoming primary-completion readouts tracked here; the soonest is “Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)”, expected around 2025-01-15.